Patents by Inventor Lorenzo DE LICHTERVELDE

Lorenzo DE LICHTERVELDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220340648
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: February 28, 2022
    Publication date: October 27, 2022
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOT, Terence Seward BAKER
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220220192
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 14, 2022
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • Anti-alpha synuclein antibodies
    Patent number: 11292831
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: April 5, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
  • Anti-alpha-synuclein antibodies
    Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20210107971
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 15, 2021
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • ANTI-ALPHA SYNUCLEIN ANTIBODIES
    Publication number: 20210101964
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 8, 2021
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOTT, Terence Seward BAKER